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Abstract There is abundant evidence that extracellular
ATP and other nucleotides have an important role in pain
signaling at both the periphery and in the CNS. The focus
of attention now is on the possibility that endogenous ATP
and its receptor system might be activated in chronic
pathological pain states, particularly in neuropathic and
inflammatory pain. Neuropathic pain is often a conse-
quence of nerve injury through surgery, bone compression,
diabetes or infection. This type of pain can be so severe that
even light touching can be intensely painful; unfortunately,
this state is generally resistant to currently available
treatments. In this review, we summarize the role of ATP
receptors, particularly the P2X4, P2X3 and P2X7 receptors,
in neuropathic and inflammatory pain. The expression of
P2X4 receptors in the spinal cord is enhanced in spinal
microglia after peripheral nerve injury, and blocking
pharmacologically and suppressing molecularly P2X4
receptors produce a reduction of the neuropathic pain
behaviour. Understanding the key roles of these ATP
receptors may lead to new strategies for the management
of intractable chronic pain.
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Abbreviations
ADP adenosine 5′-diphosphate
ATP adenosine 5′-triphosphate
ATPγS adenosine 5′-O-(3-thiotriphosphate)
BDNF brain-derived neurotrophic factor
BzATP 2′- and 3′-O-(4-benzoylbenzoyl) adenosine 5′-
triphosphate
[Ca
2+]I Intracellular Ca
2+ concentration
CD11b cluster determinant 11b
CNS central nervous system
CR3 complement receptor 3
DRG dorsal root ganglion
ERK extracellular signal-regulated protein kinase
GDNF glial cell line-derived neurotrophic factor
ICE IL-1β-converting enzyme
IL-1β interleukin-1β
IL-6 interleukin-6
INOS inducible nitric oxide synthase
InsP3 inositol 1, 4, 5-trisphosphate
JNK c-Jun N-terminal kinase
LPS lipopolysaccharide
MAPK mitogen-activated protein kinase
MEK mitogenactivated protein kinase kinase
MHC histocompatibility complex
NP nucleus pulposus
oATP oxdized ATP
PK11195 [1-(2-chlorophenyl)-N-methyl-N-(1-methyl-
propyl)-3-isoquinolineisoquinoline carboxa-
mide]
PTK protein tyrosine kinase
PTX pertussis toxin
SB203580 4-(4-fluorophenyl)-2-(4-methylsulfinyl-
phenyl)-5-(4-pyridyl)IH- imidazole
SP600125 anthra[1,9]pyrazol-6(2H)-one
SNL spinal nerve ligation
PPADS pyridoxalphosphate-6- azophenyl-2′4′-disul-
phonic acid
PKC protein kinase C
PLC phospholipase C
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Introduction
Extracellular ATP might be an important substrate in the
formation of pain [1–7]. The first clue to this possibility
was found about 30 years ago in clinical studies showing
that ATP applied to blister bases [1, 2] induced a pain
sensation in humans. Significant advances in our under-
standing of mechanisms by which ATP causes pain have
been made recently by the discovery of cell-surface
receptors for detecting extracellular ATP and other nucleo-
tides on sensory neurons [3–7]. In a subset of primary
afferent sensory neurons, ATP or its analogues produce
electrophysiological and biological responses via ligand-
gated ion-channel receptors, namely P2X receptors
(P2XRs) [8–13], and G protein-coupled receptors, namely
P2Y receptors (P2YRs) [14–19]. However, blocking
P2XRs or P2YRs pharmacologically or suppressing their
expression in sensory neurons or spinal cord had little effect
on acute physiological pain evoked by heat or mechanical
pressure in normal animals [20–22], although inflammatory
pain was attenuated [20, 23]. It seems likely that endoge-
nous ATP and its receptor system may be more prominent
in chronic pain states, particularly in neuropathic pain or
inflammatory pain, than in normal conditions [22–29].
Neuropathic pain, which often develops when nerves are
damaged through surgery, cancer, bone compression,
diabetes or infection, is a type of pathological pain that
does not resolve even when the overt tissue damage has
healed [30–32]. Neuropathic pain is so severe that even
light contact with clothing can cause intense pain (tactile
allodynia: an abnormal hypersensitivity to innocuous
stimuli) and is often resistant to most current treatments,
including morphine. Accumulating evidence concerning
how peripheral nerve injury causes neuropathic pain has
suggested that molecular and cellular alterations in the
neuronal circuit between primary sensory neurons and
spinal dorsal horn neurons after nerve injury have an
important role in the pain [30–32]. Several reports suggest
that P2X3Rs [25–27, 33, 34]o rP 2 X 7 [35, 36] have a role in
neuropathic pain. And, we recently revealed that the P2X4R
subtype in the spinal microglia is required for the
expression of neuropathic pain [37]. More recently, we
have reported that BDNF released from microglia by the
stimulation of P2X4 causes the shift in neuronal anion
gradient underlying neuropathic pain [38]. Here we review
the progress in the current understanding of how these ATP
receptors act in the pathophysiology of neuropathic and
inflammatory pain.
Microglial P2X4 and nerve injury-induced pain
Glial cells make up over 70% of the total cell population in
the CNS and are classified into astrocytes, oligodendrocytes
and microglia. Microglia are ubiquitously distributed in the
CNS and represent a morphologically unique type of cell.
In normal conditions, microglia are referred to as “resting
microglia” a n dh a v eas m a l ls o m ab e a r i n gt h i na n d
branched processes [39, 40]. Once activated by neuronal
injury, trauma, ischemia, infection, or neurological diseases,
microglia are referred to as “activated microglia” and show
a stereotypic changes in morphology (amoeboid shape),
gene expression, function and number [39–41]. The
changes in expression of cell-surface molecules (i.e.,
complement receptor 3, which is recognized by the
antibody OX42) and in morphology are widely used as
the key diagnostic markers of activated microglia [39, 40].
Clinical evidence that neuropathic pain results from
damage to peripheral nerves in humans led to the
development of a variety of animal models for studying
neuropathic pain. In most animal models of neuropathic
pain which have been intensively studied peripheral nerves
are directly damaged [42–46]. In such models, a dramatic
change in microglia within the spinal dorsal horn has been
reported after the nerve injury [47–51]. Within the first 24 h
after peripheral nerve injury, spinal microglia become
hypertrophic in their short and thick processes [47]. This
is followed by a burst proliferation of microglia with a peak
at around 2–3 days after the nerve injury [52]. Activated
microglia exhibit upregulated OX42 labeling in the dorsal
horn [47, 49–53], which starts to increase as early as 1 day
after nerve injury and peaks at around 14 days [49]. The
pattern of OX42 upregulation in the dorsal horn correlated
with that of the development of tactile allodynia [49].
Although there have been many studies showing that
activation of microglia in the dorsal horn is correlated with
the development of pain hypersensitivity in a wide variety
of nerve injury models [47, 49–54], it remained an open
question whether spinal microglia play a causal role in
neuropathic pain behaviour.
A clue to identifying P2X4 in the spinal cord as being
required for neuropathic pain first came from pharmaco-
logical investigations using the P2X antagonists TNP-ATP
and PPADS [37]. We found that the marked tactile
allodynia that develops following the nerve injury was
reversed by acutely administering TNP-ATP intrathecally
but was unaffected by administering PPADS. TNP-ATP had
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on motor behaviour. From the pharmacological profiles of
TNP-ATP (blocking P2X4 at high concentration) and
PPADS (not blocking P2X4), it was inferred that tactile
allodynia depends upon P2X4 in the spinal cord. The
expression of P2X4 protein, normally low in the naive
spinal cord, progressively increased in the days following
nerve injury with a time-course parallel to that of the
development of tactile allodynia. Double immunolableling
analysis using cell-specific markers demonstrated that
microglia in the dorsal horn on the side of the nerve injury
were intensely positive for P2X4 protein. The cells
expressing P2X4 in the nerve-injured side of the dorsal
horn were more numerous than under control conditions
and showed high levels of OX42 labeling and morpholog-
ical hypertrophy, all of which are characteristic markers of
activated microglia. Moreover, it was found that reducing
the expression of P2X4 protein in spinal microglia by
means of intrathecally administered antisense oligodeox-
ynucleotide targeting P2X4R prevented the development of
the nerve injury-induced tactile allodynia. Collectively, this
evidence implies that activation of microglial P2X4 is
necessary for pain hypersensitivity following nerve injury.
The sufficiency of P2X4 activation in microglia for the
development of allodynia was demonstrated by intrathecal
administration of activated microglia stimulated in vitro by
ATP [37]. In otherwise naive animals, intrathecal adminis-
tration of cultured microglia that were preincubated with
ATP to activate P2X4 on microglia produced tactile
allodynia progressively over the 3–5 h following the
administration. Microglia also express another subtype of
P2X, P2X7, but this receptor subtype appears not to be
involved because activation of P2X7 typically requires a
higher concentration of ATP than used [55, 56] and because
TNP-ATP, which does not affect P2X7 [57], prevents ATP
from stimulating microglia to produce allodynia. These
findings indicate that P2X4 stimulation of microglia is not
only necessary for tactile allodynia, but is also sufficient to
cause the allodynia.
Possible mechanisms underlying microglial
P2X4-related neuropathic pain
The variety of biological effects produced by ATP in
microglia during in vitro studies may provide hints towards
clarifying the mechanisms by which microglia produce
altered processing of information in the spinal cord dorsal
horn. It was recently shown that ATP-stimulated microglia
signal to lamina I neurons, causing a collapse of their
transmembrane anion gradient, and that brain-derived
neurotrophic factor (BDNF) is a crucial signaling molecule
between microglia and neurons [38]. Since it was already
reported that the nerve injury-induced tactile allodynia
depends on a depolarizing shift in the Eanion of spinal
lamina I (LI) neurons in the dorsal spinal cord, resulting in
converting the GABAA-receptor- and glycine-receptor-
mediated inhibition to excitation [58], it was considered
that microglia may affect Eanion in LI neurons. To
investigate this possibility, microglia were administered to
the lumbar spinal level of naive rats by an intrathecal
catheter as described [37]. Administering microglia stimu-
lated with ATP caused a progressive tactile allodynia over
the 5 h after injection. Voltage-clamp recording were made
from LI neurons of slices prepared 5 h after intrathecal
microglia administration. Eanion in LI neurons from rats
administered ATP-stimulated microglia was shifted to
−61.6 mV from −68.3 mV that is Eanion in spinal slices
taken from normal rats. In addition, using current clamp
recordings, GABA response switched from hyperpolarizing
in control rats to depolarizing in rats treated with ATP-
stimulated microglia. Activated microglia secrete various
biologically active molecules, one of which, BDNF, was
implicated in the hypersensitivity of dorsal horn neurons
that follows sensitization and inflammation [59–61] and in
anion gradient shifts in the hippocampus [62].
To examine whether BDNF could trigger shifts in pain
hypersensitivity and in LI neuronal Eanion similar to those
resulting from the application of ATP-stimulated microglia,
recombinant BDNF was administered intrathecally to
normal rats. BDNF produced tactile allodynia comparable
to that produced by ATP-stimulated microglia. Eanion of LI
neurons in slices treated with BDNF (>90 min, in vitro)
was significantly less negative than that of LI neurons from
control slices. During perfusion with BDNF and in the
presence of glutamate receptor blockers, the proportion of
neurons responding to GABA with a rise in [Ca
2+]i
increased over time, reaching 31% of neurons recorded
between 80 and 120 min. The rise in [Ca
2+]i was prevented
by the GABAA receptor blocker bicuculline, confirming
that the effect was mediated by GABAA receptors. Thus,
acute administration of BDNF in slices caused a depolariz-
ing shift in Eanion and caused GABA to produce net
excitation. To examine the effects of prolonged exposure
to BDNF in vivo, a BDNF-transducing recombinant
adenovirus (adBDNF) [63] was administered intrathecally
to the rats. A progressive tactile allodynia was observed
over the 4 days after the treatment of adBDNF. Eanion in LI
neurons from adBDNF-injected rats was significantly less
negative than that in LI neurons from control rats. Thus,
similar to acute administration of BDNF, sustained local
release of BDNF caused the allodynia and a depolarizing
shift in Eanion. Moreover, a function-blocking antibody
against the TrkB receptor (anti-TrkB) and a BDNF-
sequestering fusion protein (TrkB-Fc) acutely inhibited the
allodynia and the shift of Eanion of LI neurons. These
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sustain both the tactile allodynia and the depolarizing shift
in Eanion in LI neurons that result from nerve injury.
The administration of ATP-stimulated microglia with
either anti-TrkB or TrkB-Fc did not develop tactile
allodynia. After pretreatment of microglia with double-
stranded short interfering RNA directed against BDNF
(BDNF siRNA), the ATP-stimulated microglia injected
intrathecally into normal rats did not cause the allodynia.
Anti-TrkB and BDNF siRNA prevented the shift in Eanion
induced by ATP-stimulated microglia. ATP stimulation
caused release of BDNF from microglia in culture. This
effect of ATP was blocked by treating the cultures with the
P2X receptor blocker TNP-ATP. In addition, pretreatment
of the microglia with BDNF siRNA prevented release of
BDNF by ATP stimulation. By bath-application of TNP-
ATP to spinal slices taken from allodynic rats 2 weeks after
nerve injury, Eanion of LI neurons was returned to normal
value. Thus, P2X4 receptor activation is necessary to
sustain the depolarizing shift in Eanion in rats with nerve
injury. These findings show that both the decrease in paw
withdrawal threshold and the shift in Eanion in LI neurons
caused by ATP-stimulated microglia through P2X4 require
BDNF-TrkB signaling and that the source of BDNF is the
microglia themselves.
Possible involvement of P2X7 in chronic pain: TNF-α
Several cytokines, such as IL-1β, IL-6 and TNF-α, in the
dorsal horn are increased after nerve lesion [64–66] and
have been implicated in contributing to neuropathic pain
[54, 64–68].
Recent evidence indicates the relationship between TNF-
α and neuropathic pain [69–73] and TNF-α released after
injury is proposed as an initiator of abnormal pain sensation
[69–72]. TNF-α is upregulated after nerve injury in both
the DRG [73, 74] and spinal cord [64–66, 75]. The
inhibition of TNF-α reduces the hyperalgesia in neuropath-
ic pain models [76, 77]. After peripheral nerve injury, DRG
neurons robustly increase their expression of TNF-α [73].
Exogenous TNF-α applied to intact or compression-injured
DRG induces sustained mechanical allodynia [78]. How-
ever, the mechanisms by which TNF-α elicits pain behavior
are still unclear. Previous studies suggest that TNF-α mod-
ulates neuronal activity in neurons [79–85]. Schäfers et al.
[74] investigated responses of intact and nerve-injured DRG
neurons to locally applied TNF-α using parallel in vivo and
in vitro paradigms. In vivo, TNF-α (0.1–10 pg/ml) or
vehicle was injected into L5 DRG in naive rats and in rats
that had received L5 and L6 spinal nerve ligation (SNL)
immediately before injection. In naive rats, TNF-α elicits
long-lasting allodynia. In SNL rats, subthreshold doses of
TNF-α synergize with nerve injury to elicit faster onset of
allodynia and spontaneous pain behavior. Pre-emptive
treatment with etanercept, a TNF-α antagonist, reduces
SNL-induced allodynia by almost 50%. Perfusion of TNF-
α (100–1,000 pg/ml) to naive DRG neuron evokes short
lasting discharges. In injured DRG, TNF-α elicits higher and
longer lasting neuronal discharges in earlier onset at much
lower concentrations. In naive DRG which is adjacent to
injured DRG, TNF-α also elicits high-frequency discharges
at subthreshold concentrations. These data suggest that
injured and adjacent uninjured DRG neurons are sensitized
to TNF-α after SNL, and sensitization to endogenous TNF-
α may be essential for the development and maintenance of
neuropathic pain.
Microglia are a major source of TNF-α.T N F - α
following an increase in the TNF-α mRNA expression by
activating MAPKs through P2X7 in microglia. ATP
potently stimulates the release of TNF-α following an
increase in the TNF-α mRNA expression by activating
MAPKs [86, 87]. The TNF-α release is maximally elicited
by 1 mM ATP and also induced by a P2X7 receptor agonist,
BzATP, suggesting the involvement of P2X7 receptor [86].
ATP-induced TNF-α release is Ca
2+-dependent, and a
sustained Ca
2+ influx correlates with the TNF-α release.
ATP-induced TNF-α release needs MAPKs activation.
U0126, SP600125 and SB 203580, which inhibit MEK
(MAPK kinase), JNK (c-Jun N-terminal kinase), and p38,
respectively, all potently suppress the production of TNF-α
protein in ATP-stimulated microglia, whereas the produc-
tion of TNF-α mRNA is strongly inhibited by U0126 and
SP600125 but not by SB203580. This suggests that a
transcription of TNF-α mRNA is dependent on both of
ERK and JNK, but not on p38. SB203580 does not affect
the increased levels of TNF-α mRNA but does prevent
TNF-α mRNA from accumulating in the cytoplasm,
suggesting that p38 plays an important role in the
nucleocytoplasmic transport of TNF-α mRNA. The ATP-
induced activation of JNK and p38, but not ERK are
inhibited by brilliant blue G, a P2X7 receptor blocker, and
by genistein and 4-amino-5-(4-chlorophenyl)-7-(t-butyl)
pyrazolo[3,4-D] pyrimidine, which are general and src-
family-specific tyrosine kinase inhibitors, respectively.
These findings indicate that an src family acts downstream
of the P2X7 receptor to activate JNK and p38 independent-
ly from channel action [87].
In cultured DRG neurons, exogenous TNF-α activates
p38 MAPK [88]. Recently, p38 activation is shown to play
a major role in the maintenance of pain [89–92]. It is
speculated that activation of the p38 cascade may represent
a route correlating the development of pain after nerve
injury. To obtain the answer the question, it is investigated
whether TNF-α activates the p38 cascade in vivo to trigger
pain behavior after SNL [93]. As the result, etanercept
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allodynia. Interestingly, the treatment starting 1 or 7 days
after SNL is ineffective. Similarly, intrathecal infusion of a
p38 inhibitor (SB203580, 4 mg/day) is effective only when
it is started before but not 7 days after SNL. In DRG,
activated p38 is transiently elevated 5 h after SNL and
returns to baseline by 1 day after SNL. Phosphorylated p38
is localized in small TNF-α-positive DRG neurons. In
spinal cord, p38 is activated between 5 h and 3 days after
SNL and returns to baseline level within 5 days. Pretreat-
ment with etanercept blocks p38 activation only in DRG,
but not in spinal cord. These data indicate that phosphor-
ylated p38 levels in spinal cord and DRG are transiently
elevated after SNL treatment. In DRG, p38 activation is
blocked by systemic TNF-α inhibition. Another report
suggests the mechanism of TNF-α-induced pain in the line
of the interaction with brain-derived neurotrophic factor
(BDNF), which is thought to be a modulator of pain. Onda
et al. [94] investigated the effect of infliximab, a chimeric
monoclonal antibody to TNF-α, on induction of BDNF
using an experimental herniated nucleus pulposus (NP)
model. Application of NP induces a marked increase of
BDNF immunoreactivity in number in the DRG neurons
and within the superficial layer in the dorsal horn compared
with the sham group. Intraperitoneal injection with inflix-
imab reduces the BDNF induction in both DRG and spinal
cord.
Possible involvement of P2X7 in chronic pain: IL-1β
Recently, accumulating evidence indicates the relationship
between inflammatory cytokines including IL-1β and
neuropathic pain [54, 64–68]. The expression of IL-1β is
upregulated in the spinal cord of several rat mononeurop-
athy models [64–66]. Sweitzer et al. [64] investigated
whether blocking the action of central IL-1β and TNF-α
attenuates mechanical allodynia in a gender-specific man-
ner in a rodent L5 spinal nerve transection model of
neuropathic pain with/without glial activation. IL-1 receptor
antagonist, not alone but in combination with soluble TNF-
α receptor, decreases allodynia in a dose-dependent manner
with glial activation remaining. At days 3 and 7 post-
transection, the level of IL-6, but not IL-1β, in the L5
spinal cord of animals receiving daily IL-1 receptor
antagonist in combination with soluble TNF-α receptor is
significantly less than that of control animals. These
findings further support a role for central IL-1β in the
development and maintenance of neuropathic pain through
induction of a proinflammatory cytokine cascade.
Di Virgilio, Ferrari and co-workers first reported that
extracellular ATP triggers IL-1β release from LPS-treated
microglia [95–97]. They confirmed that ATP is a powerful
stimulus for IL-1β release from LPS-treated microglia and
that IL-1β release occurs much earlier than the leakage of
cytoplasmic markers. Sanz and Di Virgilio [97] examined
the kinetics and mechanism of ATP-dependent IL-1β
release from microglia. The addition of extracellular ATP
to LPS-primed microglia causes a burst release of a large
amount of processed IL-1β. ATP has no effect on the
accumulation of intracellular pro-IL-1β in the absence of
LPS. The optimal ATP concentration for IL-1β secretion is
between 3 and 5 mM, but significant release can be
observed at concentrations as low as 1 mM. At all ATP
concentrations, the IL-1β release can be inhibited by
increasing the extracellular K
+ concentration. The ATP-
dependent IL-1β release is also inhibited by the caspase
inhibitors. Authors concluded that ATP triggers accelerated
maturation and the release of intracellularly accumulated
IL-1β by activating the IL-1β-converting enzyme/caspase 1
in mouse microglia. Extracellular ATP is the only endog-
enous compound known to cause a significant reduction in
intracellular K
+ and consequent release of IL-1β [97, 98].
Substantial evidence suggests a key role of P2X7 in the
ATP-induced IL-1β release from LPS-primed microglia, i.e.,
(1) P2X7 antagonist oATP inhibits the release from micro-
glia [96], (2) microglia lacking P2X7 does not release IL-1β
after ATP stimulation [95]. Thus, it is suggested that an
activation of P2X7 by ATP induces permitting movement of
K
+,N a
+ and Ca
2+ through the cell membrane and provokes
the release of IL-1β from microglia.
Several cytokines have been reported to alter synaptic
transmission in the CNS, including the spinal cord [99,
100]. The exogenous application of IL-1β enhances
NMDA receptor-mediated Ca
2+ responses via activating
tyrosine protein kinase Src [101] which is known to
enhance NMDA receptor activity in dorsal horn neurons
[31, 102]. IL-1β also decreases GABAA receptor-mediated
currents [103]. Mechanical and thermal hyperalgesia was
absent in both inflammatory and neuropathic pain models
in mice with a disrupted P2X7 gene, while normal
nociceptive processing was preserved [35, 36], suggesting
that the stimulation of P2X7 receptor expressed by satellite
and Schwann cells causes the release of IL-1β and
upregulation of nerve growth factor, resulting in the pain.
Thus, IL-1β released from activated microglia by
activating P2X7 may also have modulatory effects on
evoking neuropathic pain.
Involvement of P2X3 or P2X2/3 on DRG neurons
in inflammatory pain
P2X-mediated nocifensive behavior is greatly enhanced in
rats with inflammation at the hind paw [23]. A similar
result was also obtained in humans [2, 104]. The stimula-
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produced the excitation of C-mechanoheat polymodal
nociceptors, which are enhanced in inflamed skin [105].
This evidence suggests that the levels of ATP in inflamed
tissues are elevated [106, 107] and P2X receptors on
peripheral nerve endings in inflamed areas would modulate
pain processing. Indeed, P2X antagonists reduce hyper-
algesia or tactile allodynia caused by complete Freund’s
adjuvant (CFA) [22, 29, 108–110], an animal model of
inflammatory pain. P2X3 antisense also reversed and
prevented hyperalgesia in a CFA model [27, 111]. P2X3
and P2X2/3 antagonist A-317491 also showed a similar
effect in a CFA model [22, 110, 112]. Mutant mice lacking
P2X3 receptors, however, showed even enhanced, thermal
hyperalgesia in a CFA model [21]. The discrepancy remains
unresolved, but it might be due to some compensatory
system resulting from P2X3 gene disruption. It is of
particular interest to note that neither A-317491 nor P2X3
antisense reduces the heightened pain sensitivity by the
carrageenan pain model [22, 111]. P2X3-knockout mice
also display the carrageenan-induced hyperalgesia as do
wild-type mice [21]. Since the inflammatory pain in the
CFA model persists much longer than that in the carra-
geenan model, P2X receptors may play more important
roles in chronic than acute inflammatory pain. This view is
supported by evidence that persistent inflammation by CFA
is accompanied by an upregulation of both P2X2 and P2X3
receptors in sensory neurons [113]. The increase in ATP
responses in inflamed DRG neurons generates large
depolarization [113]. Heightened responses via P2X recep-
tors in DRG neurons in vitro are also observed in P2X
receptors at the peripheral terminals in vivo. It was reported
that activating P2X receptors on peripheral endings produ-
ces an activation of ERK in DRG neurons only under the
situation in which peripheral tissues are inflamed [29]. The
majority of activated ERK-positive DRG neurons express
P2X3 receptors. The level of activated ERK is markedly
enhanced by mechanical stimulation given to the inflamed
hind paw, and, interestingly, the enhancement requires the
activation of P2X receptors, presumably by endogenous
ATP at the periphery. ATP is actually released from
keratinocytes by mechanical stimulation [114]. Moreover,
TNP-ATP, but not Ip5I, reduces CFA-induced mechanical
allodynia [29], suggesting the predominant role of P2X2/3
receptors. This evidence suggeststhat persistent peripheral
inflammation causes both quantitative and qualitative
upregulation of P2X receptors in sensory neurons, which
in turn leads to enhance responses of P2X receptors by
released endogenous ATP, and thereby contributes to
inflammatory pain hypersensitivity. The cellular mecha-
n i s m sb yw h i c ht h ee x p r e s s i o na n df u n c t i o no fP 2 X
receptors are upregulated in sensory neurons are still
unknown, but several possibilities are considered. Since
peripheral inflammation increases the levels of various
inflammatory mediators in the inflamed area [32, 115],
there may be an interaction between P2X receptors and
these mediators that produces the functional upregulation of
P2X receptors. Indeed, P2X-mediated responses are en-
hanced by substance P [116, 117], neurokinin B [118],
prostaglandin E2 [23], protons [119] and bradykinin [117].
Some of the regulation is mediated through the phosphor-
ylation of P2X receptors by protein kinases [117, 118]. For
the upregulation of P2X receptor expression, growth factors
could be candidates. Ramer et al. have shown that GDNF
treatment increases P2X3 expression. Interestingly, NGF
also increases the expression of P2X3 in DRG neurons and
induces new expression in some DRG neurons. The fact
that the NGF levels are dramatically elevated following
peripheral inflammation suggests that de novo expression
of P2X3 by NGF in trkA-positive DRG neurons could
contribute to the enhanced ATP signaling via P2X
receptors.
Involvement of P2X3 or P2X2/3 on DRG neurons
in neuropathic pain
Peripheral nerve injury leads to intractable neuropathic pain
that is often resistant to most current treatments [30–32].
Accumulating evidence has suggested that molecular and
cellular alterations including P2X receptors in primary
sensory neurons as well as in the dorsal horn after nerve
injury have an important role in the pathogenesis of
neuropathic pain. Transection of the sciatic nerve produces
a marked reduction of P2X3-ir in injured DRG [121]. In
contrast, an increase in the number of P2X3-ir-positive
DRG neurons is seen following partial nerve injury by
chronic constriction of the sciatic nerve [122] or of the
inferior alveolar nerve [123], both of which are also models
of neuropathic pain. The discrepancy in the change of P2X3
expression might be due to the type of nerve injury model,
since a recent study using activating transcription factor 3, a
neuronal injury maker, has shown that there is an increase
in the expression of P2X3 in DRG neurons whose axons
had been spared following partial nerve injury [33]. Besides
P2X3, the regulation of other P2X receptors also changes
following nerve injury. Messenger RNAs of P2X5 and
P2X6 are increased and decreased, respectively, in the
injured DRG [124]. Though P2X2 mRNA is unchanged,
there is a marked increase in the number of P2X2-ir-positive
neurons in the injured DRG [124]. These findings suggest
posttranscriptional alterations as well as transcriptional
changes, and raise the possibility that the composition of
P2X subunits in P2X receptor may be changed in affected
sensory neurons following nerve injury.
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by P2X3 antisense or siRNA prevents the development of
mechanical hypersensitivity by partial nerve injury of the
sciatic nerve [27, 111, 125]. Interestingly, P2X3 antisense
also reverses established neuropathic pain hypersensitivity
[27, 111], which re-emerges within several days after the
cessation of treatment with P2X3 antisense [111], suggest-
ing that the P2X3 receptor also has an ongoing role. This is
substantially supported by a recent finding that A-317491
reverses established allodynia and hyperalgesia after nerve
injury [22, 110]. It is of note that reversing or preventing
neuropathic pain behavior by P2X3 antagonists or antisense
is observed not only in partial nerve injury models that are
accompanied by the upregulation of P2X3 expression in
DRG neurons [122] but also in spinal nerve injury models
that decrease the expression of P2X3 receptors in L5 DRG
neurons without affecting their expression in L4 DRG
neurons [124, 126]. These findings indicate that P2X3
could contribute to the pathogenesis of neuropathic pain
even if P2X3 expression in sensory neurons is not
upregulated.
There are several possible mechanisms by which P2X
receptors contribute to neuropathic pain. Based on evidence
showing the presence of P2X3 receptors on peripheral nerve
endings, and because ATP is released from peripheral
tissues, including skin [5, 127, 128], P2X3 receptors in the
periphery could be involved. This might, however, not be
the case, since blocking P2X3 receptors on peripheral nerve
endings by locally injection with A-317491 does not
change the allodynia after partial nerve injury or spinal
nerve injury [110]. However, a putative role of P2X3
receptor accumulation at the proximity of the injury site of
sensory fibers [123, 129] can not be ruled out. In the dorsal
horn, P2X receptors at central terminals could be involved
since an intrathecal injection of A-317491 reverses allody-
nia [110]. Endogenous ATP may be released from central
terminals of sensory fibers by excess stimulation after nerve
injury [130], by dorsal horn interneurons [131], or by
activated dorsal horn astrocytes [132]. The released ATP
then activates P2X receptors at central terminals of the
primary afferents, and thereby enhances the release of
glutamate which results in an increase in the excitatory
transmission in dorsal horn neurons.
Conclusion
Peripheral nerve injury leads to pathological changes in the
spinal cord that cause the activation of spinal microglia.
The activated microglia express P2X4,w h i c hc a nb e
stimulated by endogenous ATP, resulting in BDNF release
and expression of neuropathic pain. Almost all currently
known drugs for neuropathic pain were developed to target
neurons, and these drugs do not exhibit adequate therapeu-
tic effects in patients with neuropathic pain [133]. We
expect that efforts to elucidate how P2X4R signaling in
microglia causes neuropathic pain will provide us both with
exciting insights into pain mechanisms and with clues to
developing new therapeutic agents which may fundamen-
tally change the management of intractable pain. P2X3
expressed by DRG neurons also plays an important role in
inflammatory and neuropathic pain. P2X7 in microglia
might be an essential molecule in producing cytokines,
TNF-α and IL-1β which are involving in the chronic pain.
These ATP receptors are thought to be new targets for drugs
managing intractable chronic pain.
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